.png){kind=icon}
.png){kind=icon}
Return
Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries
.png){kind=icon}
OA
AI
E
S
S
C
M
W
M
J
P
S
C
DOI：10.1016/j.jcf.2026.07.008.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• The median Time to Reimbursement of CFTR modulators in EU countries is 1479 days. • Around two-thirds of therapeutic indications authorised by EMA are reimbursed in EU countries. • We observed a marked variability in reimbursement timeline across EU Member States. • Higher GDP per capita and a larger pool of prevalent CF cases were associated with faster reimbursement. • Reimbursement timeline is primarily determined by the timing of manufacturer submissions to national authorities.
Keywords:
Cystic fibrosis
CFTR modulators
Regulatory approval
Reimbursement
Access to medicines
Inequality
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
6
Papers:
2.9K
Citations:
7.3K
Organization
Cited Papers